Read more about the article Safe-T: The company continues to successfully implement its growth strategy. Raised capital, launched a new web site and marketing activities, received first orders for its newly announced solution and is gearing up for dual-trading. Price target remains at NIS 9.38.

Safe-T: The company continues to successfully implement its growth strategy. Raised capital, launched a new web site and marketing activities, received first orders for its newly announced solution and is gearing up for dual-trading. Price target remains at NIS 9.38.

Continue ReadingSafe-T: The company continues to successfully implement its growth strategy. Raised capital, launched a new web site and marketing activities, received first orders for its newly announced solution and is gearing up for dual-trading. Price target remains at NIS 9.38.
Read more about the article Brainsway Ltd: The Company continues to generate consistent growth based on the rental model with sufficient cash available for 2018, without the need for further capital raising; target price unchanged.

Brainsway Ltd: The Company continues to generate consistent growth based on the rental model with sufficient cash available for 2018, without the need for further capital raising; target price unchanged.

Continue ReadingBrainsway Ltd: The Company continues to generate consistent growth based on the rental model with sufficient cash available for 2018, without the need for further capital raising; target price unchanged.
Read more about the article Brainsway Ltd: The Company continues to generate consistent growth based on the rental model with sufficient cash available for 2018; Mild setback in FDA marketing approval (OCD); Price target remains within the forecast range.

Brainsway Ltd: The Company continues to generate consistent growth based on the rental model with sufficient cash available for 2018; Mild setback in FDA marketing approval (OCD); Price target remains within the forecast range.

Continue ReadingBrainsway Ltd: The Company continues to generate consistent growth based on the rental model with sufficient cash available for 2018; Mild setback in FDA marketing approval (OCD); Price target remains within the forecast range.
Read more about the article Brainsway Ltd.: The Company continues to generate consistent growth based on the rental model; we assume operating balance in 2018; Capital raising reflects the confidence of institutional investors. Price target remains within the forecast range.

Brainsway Ltd.: The Company continues to generate consistent growth based on the rental model; we assume operating balance in 2018; Capital raising reflects the confidence of institutional investors. Price target remains within the forecast range.

Continue ReadingBrainsway Ltd.: The Company continues to generate consistent growth based on the rental model; we assume operating balance in 2018; Capital raising reflects the confidence of institutional investors. Price target remains within the forecast range.